Dr Margaret Porter Scott is currently Director of Biochemical and Cellular Pharmacology at Genentech. She and her team bring expertise in lead finding, compound mechanism of action as well as provide quantitative enzyme and cell-based assays for all of Genentech’s small molecule drug discovery programs. Previous to joining Genentech Margaret was Senior Director of Lead Discovery at Epizyme when it delivered the first-in-human small molecule inhibitors for EZH2 and DOT1L. Prior to Epizyme, Margaret had over a decade of training in drug discovery through her scientific positions at Millennium, Neogenesis, Vertex and Pfizer. Margaret received her BA from Oberlin College and her PhD from SUNY Stony Brook.